Security (S&B/CBRNE) Magazine

Spring 2017

Security & Border Protection and CST & CBRNE Source Book, published jointly, concentrate on WMD response, NGB training, counterterrorism, and border security

Issue link:

Contents of this Issue


Page 25 of 35

research has public health emergency implications. The PHEMCE's multi-use approach saves money in developing products for emer- gencies and means the product is already available in hospitals, pharmacies or ambulances and doesn't have to be shipped from a stockpile. CST & CBRNE: From a partnering perspective, how is PHEMCE working to partner with other government entities and industry to broaden and strengthen capability implementation? Dr. Korch: Each agency brings unique expertise. By coordinating closely every day through the PHEMCE, federal agencies have been able to move products seamlessly from early R&D into advanced development so they become available weeks or even months sooner than they otherwise would. Ebola is a great example. PHEMCE rep- resentatives from each agency immediately came together to review therapeutics and vaccines in the pipeline, identified the most promising, and worked collectively with aca- demia and the pharmaceutical industry to move investigational products forward at an unprecedented speed. As Zika data began emerging from Brazil, our modeling showed the virus would emerge quickly in the U.S. and its territories, thanks to mosquitoes. PHEMCE partners didn't wait. We tapped the experience of the National Institutes of Health's National Institute of Allergy and Infectious Diseases and the Walter Reed Army Institute in basic and early clinical research and BARDA's expertise in advanced development and industry partnerships to determine which technology for Zika vaccines was most likely to be effective and worth pursuing. CST & CBRNE: Any other challenges/goals that PHEMCE is addressing going forward in 2017? Dr. Korch: There are a lot of challenges. We need partners in the pharmaceutical industry working with us, and that can be a hard sell in an industry that has obligations for maximum return on investment for shareholders. Annual federal appropriations which fund development is often perceived as risky for pharmaceutical companies and their investors. The nature of the biopharma industry is a challenge, too. Devel- oping new a medical product for anything can cost roughly $1 billion and 80 percent fail; the science just doesn't work out. Most inno- vation is happening with small start-ups inexperienced in moving products into the market. We're also seeing the impact of companies moving out of par- ticular areas, like antibiotic development. Antimicrobial resistant infections can undermine an emergency response. We're exploring new business models to make medical countermeasure develop- ment more attractive to industry partners. The Nations' Premier All-Hazards Conference for Emergency Management, Public Safety and Industry Emergency Preparedness & Hazmat Response Conference October 17-19, 2017 Hosted by PA Region 13 Task Force in Partnership with US DHS/Infrastructure Protection Educational Sessions, Hands-On Training, Networking and Exhibit Hall w w w.emergenc Sheraton Station Square Pittsburgh, PA Personnel from the National Disaster Medical System conduct a drill for a CBRN incident. Medical professionals from across the United States serve as intermittent federal employees for the National Disaster Medical System to augment local health care workers during disasters. (DHHS) COMPLIMENTARY SUBSCRIPTION | scan the code to sign up now! PREPAREDNESS AND RESPONSE EMERGENCY MED COUNTERMEASURES 24 | S&BP and CST & CBRNE | Spring 2017

Articles in this issue

Links on this page

Archives of this issue

view archives of Security (S&B/CBRNE) Magazine - Spring 2017